Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes

Trial Profile

Study for the effect of visceral fat reduction by SGLT2 inhibitor Ipragliglozinin patients with type 2 diabetes

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Apr 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 03 Mar 2015 Status changed from not yet recruiting to active, no longer recruiting, according University Hospital Medical Information Network - Japan
    • 10 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top